Sanofi (SNY) EBT Margin (2009 - 2026)

Sanofi has disclosed EBT Margin across 18 years of filings, most recently posting 21.88% for Q1 2026.

• EBT Margin for Q1 2026 came in at 21.88%, down 337.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.34% (down 856.0% YoY), and the FY2025 annual result was 14.15%, down 215.0% from the prior year.
• EBT Margin came in at 21.88% for Q1 2026 at Sanofi, down from 49.31% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 49.31% in Q4 2025 to a low of 15.15% in Q2 2022.
• The 5-year median for EBT Margin is 24.66% (2025), against an average of 25.38%.
• Across the five-year window, EBT Margin soared 4251 bps in 2022 and sank 2320 bps in 2023, its largest moves.
• Sanofi's EBT Margin stood at 42.36% in 2022, then slumped by 55 bps to 19.16% in 2023, then soared by 34 bps to 25.58% in 2024, then surged by 93 bps to 49.31% in 2025, then plunged by 56 bps to 21.88% in 2026.
• The last three EBT Margin figures came in at 21.88% (Q1 2026), 49.31% (Q4 2025), and 24.66% (Q3 2025), per Business Quant data.